We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

IP Attys Back Regeneron Over Inequitable Conduct Finding

Law360, New York (October 2, 2017, 6:04 PM EDT) -- Numerous intellectual property law organizations and lawyers are calling for the full Federal Circuit to review its panel decision affirming that a Regeneron Pharmaceuticals Inc. patent is unenforceable in part because of inequitable conduct of litigators during a later infringement case, arguing it could “seriously and negatively affect the course of patent prosecution.”

The Intellectual Property Law Associations of both New York and Chicago, as well as the Washington Legal Foundation, the Biotechnology Innovation Organization and various practicing lawyers in the IP field all filed amicus...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.